Peptidic materials that traffic efficiently to the cell cytosol and nucleus

Patent metadata

Field	Value
Publication number	US-11865181-B2
Application number	US-201816761364-A
Country	US
Kind code	B2
Filing date	Nov 2, 2018
Priority date	Nov 3, 2017
Publication date	Jan 9, 2024
Grant date	Jan 9, 2024

Abstract

This invention is generally related to modified peptidic oligomers that have an increased ability to reach the cytosol or nucleus. In some embodiments, the modified peptidic oligomer molecules deliver an associated cargo molecule to the cytosol or nucleus. Other embodiments of the invention relate to modified peptidic oligomer fusion molecules that reach the cytosol or nucleus.

First claim

What is claimed is:

1. A modified peptidic oligomer comprising at least 5 cationic residues, wherein the at least 5 cationic residues are residues at positions i, i+3, i+4, i+7, and i+8 with respect to the first cationic residue, wherein the peptidic oligomer further comprises at least two unnatural amino acid residues selected from the group consisting of (R)-2-(7′-octenyl)alanine (R 8 ), (S)-2-(4′-pentenyl)alanine (S 5 ), (R)-2-(4′-pentenyl)alanine (R 5 ), and (S)-2-(7′-octenyl)alanine and a hydrocarbon staple formed between the two unnatural amino acid residues, and wherein the amino acid sequence of the peptidic oligomer is selected from the group consisting of SEQ ID NO:5 and SEQ ID NO:11.

2. The modified peptidic oligomer of claim 1 , wherein the modified peptidic oligomer is incorporated into a fusion molecule comprising a modified peptidic oligomer domain (MPOD) and a cargo domain.

3. The fusion molecule of claim 2 , wherein the cargo domain comprises at least one selected from the group consisting of a small molecule, a nucleic acid and a polypeptide.

4. The fusion molecule of claim 2 , wherein the cargo domain is fused to the C-terminus of the MPOD.

5. The fusion molecule of claim 2 , wherein the cargo domain is fused to the N-terminus of the MPOD.

6. The fusion molecule of claim 2 , further comprising at least one selected from the group consisting of a linker and a label.

7. The modified peptidic oligomer of claim 6 , wherein the label is a Rhodamine label.

8. A composition comprising a modified peptidic oligomer of claim 1 and at least one cargo molecule.

9. The composition of claim 8 , wherein at least one cargo molecule comprises at least one selected from the group consisting of a small molecule, a nucleic acid and a polypeptide.

10. The composition of claim 8 , wherein at least one cargo molecule is not covalently bound to the modified peptidic oligomer.

11. A method of promoting transduction of a cargo molecule into the cytosol or nucleus of a cell of a subject, the method comprising administering to the subject a therapeutically effective amount of the composition of claim 8 .

12. The method of claim 11 , wherein the subject is human.

13. A modified peptidic oligomer comprising at least 5 cationic residues, wherein the modified peptidic oligomer comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11 and SEQ ID NO:12.

Assignees

• Univ Yale

Inventors

• Shrader Alanna Schepartz
• Quach Kim

Classifications

• A61K47/6455 Primary

  Polycationic oligopeptides, polypeptides or polyamino acids, e.g. for complexing nucleic acids · CPC title

• A61K49/0041

  Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal (in vivo G01N) · CPC title

• C07K7/02

  Linear peptides containing at least one abnormal peptide link · CPC title

• C07K14/4746 Primary

  p53 · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title